Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, FDA

Every Second Counts: BIOTRONIK's PK Papyrus Stent for Coronary Perforations Approved for Use in the US


LAKE OSWEGO, Ore., Sept. 14, 2018 /PRNewswire/ -- BIOTRONIK today announced the FDA approval of the PK Papyrus covered coronary stent system under Humanitarian Device Exemption for use in the emergency treatment of acute coronary perforations.1,2 PK Papyrus received CE marking in 2013.

Built on BIOTRONIK's ultrathin stent platform, PK Papyrus is the first FDA approved device for the treatment of acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter.

Built on BIOTRONIK's ultrathin stent platform, PK Papyrus is the first FDA approved device for the treatment of acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter. The covered stent is available in 17 sizes, expanding treatment options and helping avoid the need for emergency coronary artery bypass grafting. PK Papyrus is the only 5 French compatible covered coronary stent available in the United States.

"In rare cases of a coronary perforation, time is the enemy," said Dr. Dean Kereiakes, Interventional Cardiologist and Medical Director of The Christ Hospital and Vascular Center, Cincinnati, Ohio. "The device's superior flexibility and tracking means that PK Papyrus delivers more like a conventional stent and can treat a perforation more quickly, avoiding further complications. Hospitals need to have this potentially lifesaving device ready for physicians to use."

The ultrathin, single-stent design and unique electrospun polyurethane membrane contribute to PK Papyrus' superior performance. BIOTRONIK's covered stent is 58 percent more flexible3 and has a 23 percent smaller crossing profile compared to Graftmaster.4 The latter has a layered dual-stent design and is the only other covered coronary stent available in the United States.

"Perforation is very uncommon, but physicians need to be fully prepared for this emergency event," said Marlou Janssen, President of BIOTRONIK, Inc. "It's unacceptable that this critical care area has seen no innovation in nearly two decades. PK Papyrus has been trusted in various international markets since 2013. BIOTRONIK saw a need, rose to the occasion and invested in bringing this stent to the United States. We made this decision because patient care is paramount and we are committed to helping physicians and hospitals save lives and improve patient outcomes."

Fewer than 4,000 percutaneous coronary interventions per year in the United States require a covered stent, classifying PK Papyrus as a Humanitarian Use Device. BIOTRONIK will make the lifesaving product PK Papyrus available to US physicians in 2019 in alignment with BIOTRONIK's goal to receive FDA approval for the full range of a highly innovative Vascular Intervention portfolio.

References
1 Humanitarian Device. Authorized by Federal law for use in the treatment of acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter. The effectiveness of this device for this use has not been demonstrated.
2 Institutional Review Board approval is required for use.
3 Compared to Jostent Graftmaster 3.0/16 (BIOTRONIK data on file).
4 Compared to Graftmaster 2.8/16 (BIOTRONIK data on file).

Jostent and Graftmaster are registered trademarks of the Abbott Group of Companies.

About BIOTRONIK
BIOTRONIK is a medical technology company that develops trusted and innovative cardiovascular and endovascular solutions. Driven by purpose and integrity, BIOTRONIK has partnered with hospitals and health systems for more than 50 years, helping to deliver care that saves and improves the lives of millions of patients with heart and blood vessel diseases. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. BIOTRONIK has US offices in New York City and Lake Oswego, Oregon.

For more information, visit: www.biotronik.com 
Connect on Facebook, Twitter, LinkedIn and YouTube.

BIOTRONIK is a leader in cardio- and endovascular medical technology. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. (PRNewsFoto/BIOTRONIK)

SOURCE BIOTRONIK


These press releases may also interest you

at 05:34
Sungrow, a global leading PV inverter and energy storage system supplier, has emerged as one of the standout companies on the 2024 Fortune Asia Future 30 list. The list, which recognizes the most promising companies in Asia Pacific, is a testament to...

at 05:30
Cato Networks, the SASE leader, announced a new SASE throughput record here at the Porsche Studio Ginza ahead of the 2024 Tokyo E-Prix, achieving 10 Gbps without hardware upgrades. At 10 Gbps, Cato became the first SASE platform to compete not only...

at 05:20
Roborock, a global leader in ultra-intelligent home robotics engineered to simplify daily life, today announced it has taken the number one spot for robotic vacuum sales worldwide, according to new data by Euromonitor. Celebrating its achievements at...

at 05:20
IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced that China National Medical Products Administration (NMPA) has approved the...

at 05:15
The "Flow Cytometry Markets. Forecasts by Technology, Product and Application. With Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. The technology is moving faster than the market. Find the...

at 05:00
TAL Education Group ("TAL" or the "Company") , a smart learning solutions provider in China, today announced that it will release its unaudited financial results for the fourth quarter and fiscal year 2024 ended February 29, 2024, before the market...



News published on and distributed by: